
Claims

1. A pharmaceutical composition for eradicating *Helicobacter pylori*, comprising: a compound represented by a following formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof as an active ingredient:

[Formula 1]




wherein the pharmaceutical composition increases an intragastric pH to 5 or more within three hours after administration thereof, and

wherein a percentage of time at which an intragastric pH is maintained at 5.0 or more for a period of up to 24 hours after administration thereof is at least 60% in case of the pharmaceutical composition.

2. The pharmaceutical composition according to claim 1, wherein the compound represented by the formula 1 is a compound represented by a following formula 2:

[Formula 2]



3. The pharmaceutical composition according to claim 1, wherein the composition comprises 10 mg to 500 mg of the compound represented by the formula 1 or pharmaceutically acceptable salts thereof, 100 mg to 4 g of amoxicillin or pharmaceutically acceptable salts thereof, and 50 mg to 3 g of clarithromycin or pharmaceutically acceptable salts thereof.

4. The pharmaceutical composition according to claim 1, wherein a percentage of time at which an intragastric pH is maintained at ~~5~~6.0 or more for a period of up to 24 hours after administration thereof is at least ~~60~~80% in case of the pharmaceutical composition.

5. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition increases an intragastric pH to ~~5~~–6.0 or more within ~~three~~two hours after administration thereof.

6. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition eradicates *Helicobacter pylori* resistant to antibiotics.

7. The pharmaceutical composition according to claim 6, wherein the *Helicobacter pylori* resistant to antibiotics is resistant to amoxicillin or clarithromycin.

8. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is administered into subjects infected with *Helicobacter pylori*.


9. The pharmaceutical composition according to claim 8, wherein the *Helicobacter pylori* is *Helicobacter pylori* resistant to antibiotics.

10. The pharmaceutical composition according to claim 9, wherein the *Helicobacter pylori* resistant to antibiotics is resistant to amoxicillin or clarithromycin.

11. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is an oral administration type.

12. A combination for eradicating *Helicobacter pylori*, comprising: a compound represented by a following formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof:

[Formula 1]




wherein the combination increases an intragastric pH to 5 or more within three hours after administration thereof, and

wherein a percentage of time at which an intragastric pH is maintained at 5.0 or more for a period of up to 24 hours after administration thereof is at least 60% in case of the combination.

~~13. The combination according to claim 12, wherein the combination is for eradicating *Helicobacter pylori*.~~

~~14~~13. A kit~~, comprising a combination~~ for eradicating *Helicobacter pylori*, comprising a combination comprising: a compound represented by a following formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof:

[Formula 1]




wherein the combination increases an intragastric pH to 5 or more within three hours after administration thereof, and

wherein a percentage of time at which an intragastric pH is maintained at 5.0 or more for a period of up to 24 hours after administration thereof is at least 60% in case of the combination.

~~15. A method for eradicating *Helicobacter pylori*, comprising a step of administering a pharmaceutical composition, comprising: a compound represented by a following formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof as an active ingredient, into subjects in need:~~


~~[Formula 1]~~



~~16~~14. A use of a compound represented by a following formula 1, optical isomers

thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof, in preparing a drug for eradicating *Helicobacter pylori*:

[Formula 1]




wherein the drug increases an intragastric pH to 5 or more within three hours after administration thereof, and

wherein a percentage of time at which an intragastric pH is maintained at 5.0 or more for a period of up to 24 hours after administration thereof is at least 60% in case of the drug.


~~17. A use of a compound represented by a following formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof in eradicating *Helicobacter pylori*:~~

~~[Formula 1]~~



15. The use according to claim 14, wherein the compound represented by the formula 1 is a compound represented by a following formula 2:

[Formula 2]



16. The use according to claim 14, wherein a content of the compound represented by the formula 1 or pharmaceutically acceptable salts thereof is 10 mg to 500 mg, a content of amoxicillin or pharmaceutically acceptable salts thereof is 100 mg to 4 g, and a content of clarithromycin or pharmaceutically acceptable salts thereof is 50 mg to 3 g.

17. The use according to claim 14, wherein a percentage of time at which an intragastric pH is maintained at 6.0 or more for a period of up to 24 hours after administration thereof is at least 80% in case of the compound represented by the formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or

pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof.

18. The use according to claim 14, wherein the compound represented by the formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof increase an intragastric pH to 6.0 or more within two hours after administration thereof.

19. The use according to claim 14, wherein the compound represented by the formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof eradicate *Helicobacter pylori* resistant to antibiotics.

20. The use according to claim 19, wherein the *Helicobacter pylori* resistant to antibiotics is resistant to amoxicillin or clarithromycin.

21. The use according to claim 14, wherein the compound represented by the formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or

pharmaceutically acceptable salts thereof are administered into subjects infected with *Helicobacter pylori*.

22. The use according to claim 21, wherein the *Helicobacter pylori* is *Helicobacter pylori* resistant to antibiotics.

23. The use according to claim 22, wherein the *Helicobacter pylori* resistant to antibiotics is resistant to amoxicillin or clarithromycin.

24. The use according to claim 14, wherein the compound represented by the formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof are prepared into an oral administration type.